{
  "paper_metadata": {
    "pmid": "33127389",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted variants in the BRCA2 gene, including clinical significance, penetrance data, and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.3848_3849del",
      "protein_notation": "p.Val1283fs",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "not specified",
        "phenotype": "resectable PDAC"
      },
      "penetrance_data": {
        "total_carriers_observed": 6,
        "affected_count": 6,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "resectable PDAC with elevated CA199",
          "evidence_sentence": "The first patient had two BRCA2 mutations, one classified as pathogenic (V1283fs \u00d7 2) and one classified as VUS (D820E), and was treated with off-label PARP inhibitor."
        }
      ],
      "functional_data": {
        "summary": "The pathogenic mutation is associated with sensitivity to platinum-based chemotherapy and PARP inhibitors.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The patient was treated with a PARP inhibitor and had a significant response.",
      "key_quotes": [
        "The first patient had two BRCA2 mutations, one classified as pathogenic (V1283fs \u00d7 2) and one classified as VUS (D820E), and was treated with off-label PARP inhibitor."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.6485_6486del",
      "protein_notation": "p.Lys2162fs",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "not specified",
        "phenotype": "metastatic disease"
      },
      "penetrance_data": {
        "total_carriers_observed": 6,
        "affected_count": 6,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "metastatic disease with a liver lesion",
          "evidence_sentence": "The second patient with a BRCA2 mutation was diagnosed with metastatic disease with a liver lesion found during surgical exploration."
        }
      ],
      "functional_data": {
        "summary": "The pathogenic mutation is associated with sensitivity to platinum-based chemotherapy and PARP inhibitors.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The patient was enrolled in a clinical trial with a PARP inhibitor plus FOLFOX.",
      "key_quotes": [
        "The second patient with a BRCA2 mutation was diagnosed with metastatic disease with a liver lesion found during surgical exploration."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.4697del",
      "protein_notation": "p.Tyr1566fs",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "not specified",
        "phenotype": "recurrent disease"
      },
      "penetrance_data": {
        "total_carriers_observed": 6,
        "affected_count": 6,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "recurrent disease after surgery",
          "evidence_sentence": "The primary tumor was then sequenced, and a pathogenic BRCA2 mutation (T1566fs \u00d7 9) was reported."
        }
      ],
      "functional_data": {
        "summary": "The pathogenic mutation is associated with sensitivity to platinum-based chemotherapy and PARP inhibitors.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The patient received a PARP inhibitor in a clinical trial but unfortunately progressed after only one cycle.",
      "key_quotes": [
        "The primary tumor was then sequenced, and a pathogenic BRCA2 mutation (T1566fs \u00d7 9) was reported."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 5",
      "table_caption": "Pathogenic and VUS mutations in HRD genes",
      "variants_extracted": 3
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 3,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data was extracted from the main text and tables."
  }
}